Candidiasis - Pipeline Review (H2 2018) by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Candidiasis - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. Candidiasis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 8, 3, 27, 9 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 9 molecules, respectively. Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies FeaturedAmplyx Pharmaceuticals Inc APEIRON Biologics AG Bakker Medical Srl Beta Pharma Inc Bionex Pharmaceuticals LLC Biosergen AS Cellix Bio Pvt Ltd Cidara Therapeutics Inc General Biologicals Corp Grupo Ferrer Internacional SA Helix BioMedix Inc iCo Therapeutics Inc Matinas BioPharma Holdings Inc Nanomerics Ltd Nosopharm SAS Novabiotics Ltd NovaDigm Therapeutics Inc Novartis AG Onxeo SA Pulmocide Ltd Scynexis Inc Sealife PHARMA GMBH Viamet Pharmaceuticals Inc Visterra Inc Wellstat Vaccines LLC
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/33g88b/candidiasis?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005313/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/19/2018 06:22 AM/DISC: 09/19/2018 06:22 AM